The opening days of 2026 have seen a clutch of UK retailers roll out products with an eye on the rising number of people ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...

Dec. 30, 2025 – updated Jan. 5, 2026 – Injectable GLP-1 drugs have transformed obesity treatment – and now they're going oral. "It's good to have more options for patients with obesity," said Melanie ...

The U.S. Food and Drug Administration just approved the pill form of weight-loss drug Wegovy for use in the U.S. The daily oral medication, made by Novo Nordisk, is the first of its kind used to treat ...

A growing body of research suggests that older adults are discontinuing GLP-1 medications at high rates, The New York Times reported Dec. 21. 2. Experts said stopping GLP-1 therapy often leads to ...

Over the last few years, taking a GLP-1 medication — drugs like Ozempic, Wegovy and Zepbound — has become an ordinary experience in the United States with important implications for Americans’ health.

GLP-1 medications have reached a level of household penetration that food and beverage brands can no longer ignore, but the impact on grocery sales is unfolding more gradually than some might expect.

Jess Loren remembers loving the taste of Cap'n Crunch cereal. Coca-Cola. Snickers bars. But now, instead of a sweetness, "they taste bland," she says. Flavors are noticeably muted since she started a ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality compared with those not taking the drugs. The mortality benefit was statistically ...

Linda McMahon, 57, chuckled recalling her Thanksgiving with the "Mounjaro crew" — herself and friends who are taking GLP-1 medications. "If you saw our plates you would have laughed," she said.

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in record numbers, providers are warning of a troubling ripple effect: ...